Impact of the sharp changes in the use of contraception in 2013 on the risk of pulmonary embolism in France

Journal of Thrombosis and Haemostasis

Volumn 13, Issue 9, 2015, Pages 1576-1580

  Tricotel, A ^a   Collin, C ^a   Zureik, M ^a  

^a French National Agency for Medicines and Health Products Safety (ANSM)   (France)

Author keywords

Contraceptives, oral, combined; Epidemiology; Hospitalization; Public health; Pulmonary embolism

Indexed keywords

LEVONORGESTREL; NORETHISTERONE; NORGESTIMATE; NORGESTREL; ORAL CONTRACEPTIVE AGENT;

ADOLESCENT; ADULT; ARTICLE; COMPARATIVE STUDY; CONTRACEPTION; CONTROLLED STUDY; FEMALE; FEMALE CONTRACEPTIVE DEVICE; FRANCE; GROUPS BY AGE; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; INCIDENCE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MORBIDITY; PRIORITY JOURNAL; RISK ASSESSMENT; RISK REDUCTION; TREND STUDY; VAGINA RING; VAGINAL PATCH; YOUNG ADULT; CHEMICALLY INDUCED; CLASSIFICATION; COMPLICATION; DRUG UTILIZATION; MALE; MIDDLE AGED; PROCEDURES; PULMONARY EMBOLISM; STATISTICS AND NUMERICAL DATA; THROMBOPHILIA; TRENDS; UTILIZATION;

ADOLESCENT; ADULT; CONTRACEPTION; CONTRACEPTIVES, ORAL, COMBINED; CONTRACEPTIVES, ORAL, HORMONAL; DRUG UTILIZATION; FEMALE; FRANCE; HOSPITALIZATION; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PULMONARY EMBOLISM; THROMBOPHILIA; YOUNG ADULT;

EID: 84940843708     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.13053     Document Type: Article

References (20)

1. Marion L. When the injustice becomes a fight. Le Monde.fr. http://www.lemonde.fr/sante/article/2014/07/29/marion-larat-l-injustice-transformee-en-combat_1806568_1651302.html (accessed 15 May 2015).
2. Jordan WM, Anand JK. Pulmonary embolism. Lancet 1961; 278: 1146-7.
3. French National Agency for Medicines and Health Products Safety (ANSM). Combined oral contraceptives and risk of venous thromboembolism: second-generation pills should be used in a first line indication. 2012. http://ansm.sante.fr/S-informer/Points-d-information-Points-d-information/Contraceptifs-oraux-combines-et-risque-de-thrombose-veineuse-prescription-des-pilules-de-2e-generation-contenant-du-levonorgestrel-en-premiere-intention-Point-d-information (accessed 15 May 2015).
4. French National Authority for Health. Combined oral contraceptives: use of first- and second-generation pills in a first line indication. 2012. http://www.has-sante.fr/portail/upload/docs/application/pdf/2012-12/contraceptis_oraux_3_g_fiche_bum.pdf (accessed 15 May 2015).
5. Helmerhorst FM, Rosendaal FR. Is an EMA review on hormonal contraception and thrombosis needed? BMJ 2013; 346: f1464.
6. Bajos N, Rouzaud-Cornabas M, Panjo H, Bohet A, Moreau C, Fecond Research Team. The French pill scare: towards a new contraceptive model? Popul Soc 2014; 511. http://www.ined.fr/fr/publications/population-et-societes/crise-pilule-france-nouveau-modele-contraceptif/ (accessed 15 May 2015).
7. Lemaitre M, Lastennet G, Syr D, Emmerich J, Zureik M. Impact of the 2013 French pill crisis on women's behaviour regarding contraception. Drugs Real World Outcomes 2015; 2: 13-22.
8. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet 1995; 346: 1582-8.
9. Bloemenkamp KW, Rosendaal FR, Helmerhorst FM, Büller HR, Vandenbroucke JP. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet 1995; 346: 1593-6.
10. Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis C. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995; 346: 1589-93.
11. Spitzer WO, Lewis MA, Heinemann LA, Thorogood M, MacRae KD. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Transnational Research Group on oral contraceptives and the health of young women. BMJ 1996; 312: 83-8.
12. Lidegaard Ø, Løkkegaard E, Svendsen AL, Agger C. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ 2009; 339: b2890.
13. Lidegaard Ø, Nielsen LH, Skovlund CW, Skjeldestad FE, Løkkegaard E. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-2009. BMJ 2011; 343: d6423.
14. Parkin L, Sharples K, Hernandez RK, Jick SS. Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case-control study based on UK General Practice Research Database. BMJ 2011; 342: d2139.
15. Jick SS, Hernandez RK. Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United States claims data. BMJ 2011; 342: d2151.
16. National Institute of Statistics and Economic Studies (Insee). Population by sex and by five-year age group. http://www.insee.fr (accessed 15 May 2015).
17. Website of Technical Hospitalization Information Agency (ATIH). http://www.atih.sante.fr/ (accessed 15 May 2015).
18. Tricotel A, Raguideau F, Collin C, Zureik M. Estimate of venous thromboembolism and related-deaths attributable to the use of combined oral contraceptives in France. PLoS ONE 2014; 9: e93792.
19. Casez P, Labarère J, Sevestre MA, Haddouche M, Courtois X, Mercier S, Lewandowski E, Fauconnier J, François P, Bosson JL. ICD-10 hospital discharge diagnosis codes were sensitive for identifying pulmonary embolism but not deep vein thrombosis. J Clin Epidemiol 2010; 63: 790-7.
20. IMS-Health (n.d.) MS MIDAS Market Segmentation. IMS Health website. http://www.imshealth.com/deployedfiles/i?ms/Global/Content/Solutions/Solutions%20?by%20Sector/Pharmaceutical/Mkt_Seg_Broch?ure.pdf. (accessed 15 May 2015).